Stuart, A., Shaw, R., Liu, X., Greenland, M., Aley, P., Andrews, N., Cameron, C., Charlton, S., Clutterbuck, E., Collins, A., Darton, T., Dinesh, T., Duncan, C., England, A., Faust, S., Ferreira, D., Finn, A., Goodman, A., Green, C., Hallis, B., Heath, P., Hill, H., Horsington, B., Lambe, T., Lazarus, R., Libri, V., Lillie, P., Mujadidi, Y., Payne, R., Plested, E., Provstgaard-Morys, S., Ramasamy, M., Ramsay, M., Read, R., Robinson, H., Screaton, G., Singh, N., Turner, D., Turner, P., Vichos, J., White, R., Nguyen-Van-Tam, J., Snape, M. & Com-COV2 Study Group 2021, 'Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial', The Lancet. https://doi.org/10.1016/S0140-6736(21)02718-5